Base de dados : MEDLINE
Pesquisa : D02.640.672.580 [Categoria DeCS]
Referências encontradas : 74 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 8 ir para página                    

  1 / 74 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26397148
[Au] Autor:Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Overgaard J; Grau C
[Ad] Endereço:a Department of Experimental Clinical Oncology , Aarhus University Hospital , Denmark.
[Ti] Título:Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
[So] Source:Acta Oncol;54(9):1673-7, 2015.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço/radioterapia
Nimorazol/uso terapêutico
Garantia da Qualidade dos Cuidados de Saúde
Radiossensibilizantes/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto/normas
[Mh] Termos MeSH secundário: Carcinoma de Células Escamosas
Fracionamento de Dose
Fidelidade a Diretrizes
Seres Humanos
Auditoria Médica
Estudos Multicêntricos como Assunto
Guias de Prática Clínica como Assunto
Estudos Retrospectivos
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:151020
[Lr] Data última revisão:
151020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150924
[St] Status:MEDLINE
[do] DOI:10.3109/0284186X.2015.1074721


  2 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26344652
[Au] Autor:Feketeová L; Plekan O; Goonewardane M; Ahmed M; Albright AL; White J; O'Hair RA; Horsman MR; Wang F; Prince KC
[Ad] Endereço:School of Chemistry and Bio21 Institute of Molecular Science and Biotechnology, The University of Melbourne , 30 Flemington Road, 3010 Parkville, Victoria, Australia.
[Ti] Título:Photoelectron Spectra and Electronic Structures of the Radiosensitizer Nimorazole and Related Compounds.
[So] Source:J Phys Chem A;119(39):9986-95, 2015 Oct 01.
[Is] ISSN:1520-5215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Soft X-ray photoelectron spectroscopy has been used to investigate the radiosensitizer nimorazole and related model compounds. We report the valence and C, N, and O 1s photoemission spectra and K-edge NEXAFS spectra of gas-phase nimorazole, 1-methyl-5-nitroimidazole, and 4(5)-nitroimidazole in combination with theoretical calculations. The valence band and core level spectra are in agreement with theory. We determine the equilibrium populations of the two tautomers in 4(5)-nitroimidazole and find a ratio of 1:0.7 at 390 K. The NEXAFS spectra of the studied nitroimidazoles show excellent agreement with spectra of compounds available in the literature that exhibit a similar chemical environment. By comparing 1-methyl-5-nitroimidazole (single tautomer) with 4(5)-nitroimidazole, we are able to disentangle the photoemission and photoabsorption spectra and identify features due to each single tautomer.
[Mh] Termos MeSH primário: Modelos Teóricos
Nimorazol/química
Espectroscopia Fotoeletrônica/métodos
Radiossensibilizantes/química
[Mh] Termos MeSH secundário: Modelos Moleculares
Estrutura Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:151001
[Lr] Data última revisão:
151001
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150908
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jpca.5b05950


  3 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26329662
[Au] Autor:Wittenborn TR; Horsman MR
[Ad] Endereço:a Department of Experimental Clinical Oncology , Aarhus University Hospital , Aarhus , Denmark.
[Ti] Título:Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy.
[So] Source:Acta Oncol;54(9):1385-92, 2015.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hypoxia is a characteristic feature of solid tumours that significantly reduces the efficacy of conventional radiation therapy. In this study we investigated the role of hypoxia in a stereotactic radiation schedule by using a variety of hypoxic modifiers in a preclinical tumour model. MATERIAL AND METHODS: C3H mammary carcinomas were irradiated with 3 × 15 Gy during a one-week period, followed three days later by a clamped top-up dose to produce a dose response curve; the endpoint was tumour control. The hypoxic modifiers were nimorazole (200 mg/kg), nicotinamide (120 mg/kg) and carbogen (95% O2 + 5% CO2) breathing, OXi4503 (10 mg/kg), and hyperthermia (41.5°C; 1 h). RESULTS: The radiation dose controlling 50% of clamped tumours (TCD50) following 3 × 15 Gy was 30 Gy. Giving nimorazole or nicotinamide+ carbogen prior to the final 15 Gy fraction non-significantly (χ(2)-test; p < 0.05) reduced this TCD50 to 20-23 Gy; when administered with each 3 × 15 Gy fraction these values were significantly reduced to ≤ 2.5 Gy. Injecting OXi4503 or heating after irradiating significantly reduced the TCD50 to 9-12 Gy regardless of whether administered with one or all three 15 Gy fractions. Combining OXi4503 and heat with the final 15 Gy had a significantly larger effect (TCD50 = 2 Gy). CONCLUSIONS: Clinically relevant modifiers of hypoxia effectively enhanced an equivalent stereotactic radiation treatment confirming the importance of hypoxia in such schedules.
[Mh] Termos MeSH primário: Hipóxia Celular
Neoplasias Mamárias Experimentais/terapia
Radiocirurgia
[Mh] Termos MeSH secundário: Administração por Inalação
Animais
Dióxido de Carbono/administração & dosagem
Difosfatos/farmacologia
Feminino
Hipertermia Induzida
Neoplasias Mamárias Experimentais/metabolismo
Camundongos Endogâmicos C3H
Niacinamida/farmacologia
Nimorazol/farmacologia
Oxigênio/administração & dosagem
Oxigênio/metabolismo
Radiossensibilizantes/administração & dosagem
Dosagem Radioterapêutica
Estilbenos/farmacologia
Complexo Vitamínico B/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Diphosphates); 0 (Oxi 4503); 0 (Radiation-Sensitizing Agents); 0 (Stilbenes); 12001-76-2 (Vitamin B Complex); 142M471B3J (Carbon Dioxide); 25X51I8RD4 (Niacinamide); 469ULX0H4G (Nimorazole); 8063-77-2 (carbogen); S88TT14065 (Oxygen)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:151020
[Lr] Data última revisão:
151020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150903
[St] Status:MEDLINE
[do] DOI:10.3109/0284186X.2015.1064162


  4 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25913070
[Au] Autor:Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
[Ad] Endereço:Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark. Electronic address: hassan@oncology.dk.
[Ti] Título:IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
[So] Source:Radiother Oncol;116(1):15-20, 2015 Jul.
[Is] ISSN:1879-0887
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To test the hypothesis that radiotherapy (RT) of head and neck squamous cell carcinoma (HNSCC) can be improved by hypoxic modification using nimorazole (NIM) in association with accelerated fractionation. MATERIALS AND METHODS: The protocol was activated in March 2012 as an international multicenter randomized trial in patients with HNSCC. Tumors were treated to a dose of 66-70Gy, 33-35 fractions, 6 fractions per week. NIM was administered in a dose of 1.2gperm(2), 90min before the first daily RT fraction. The primary endpoint was loco-regional failure. The trial was closed prematurely by June 2014 due to poor recruitment. An associated quality assurance program was performed to ensure the consistency of RT with the protocol guidelines. RESULTS: The trial was dimensioned to include 600 patients in 3years, but only 104 patients were randomized between March 2012 and May 2014 due to the inability to involve three major centers and the insufficient recruitment rate from the other participating centers. Twenty patients from two centers had to be excluded from the analysis due to the unavailability of the follow-up data. Among the remaining 84 patients, 82 patients were evaluable (39 and 43 patients in the RT+NIM and the RT-alone arms, respectively). The treatment compliance was good with only six patients not completing the full planned RT course, and 31 patients (79%) out of 39 allocated for NIM, achieving at least 90% of the prescribed drug dose. At the time of evaluation, 40 patients had failed to achieve persistent loco-regional tumor control, and a total of 45 patients had died. The use of NIM improved the loco-regional tumor control with an 18month post-randomization cumulative failure rate of 33% versus 51% in the control arm, yielding a risk difference of 18% (CI -3% to 39%; P=0.10). The corresponding values for overall death was 43% versus 62%, yielding a risk difference of 19% (CI -3% to 42%; P=0.10). Sixteen patients, out of 55 patients analyzed for hypoxic gene expression, were classified as having more hypoxic tumors. Such patients, if treated with RT alone, had a higher loco-regional tumor failure rate as compared to the rest of the patients with known hypoxic status (P=0.05). CONCLUSION: Although the trial was incomplete and suffered from a small number of patients, the results suggested an improvement in loco-regional tumor control and overall survival in patients with advanced HNSCC given the hypoxic modifier NIM in addition to accelerated fractionation RT. However, the trial also revealed that conducting multicenter and multinational study combining drug and RT in developing countries may suffer from uncontrolled and unsolvable problems.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/radioterapia
Neoplasias de Cabeça e Pescoço/radioterapia
Nimorazol/uso terapêutico
Radiossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Carcinoma de Células Escamosas/genética
Carcinoma de Células Escamosas/patologia
Fracionamento de Dose
Feminino
Regulação Neoplásica da Expressão Gênica
Neoplasias de Cabeça e Pescoço/genética
Neoplasias de Cabeça e Pescoço/patologia
Seres Humanos
Hipóxia/genética
Masculino
Meia-Idade
Estadiamento de Neoplasias
Cooperação do Paciente
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150428
[St] Status:MEDLINE


  5 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25845449
[Au] Autor:Das S; Dubey R; Roychowdhury S; Ghosh M; Sinha BN; Kumar Pradhan K; Bal T; Muthukrishnan V; Seijas JA; Pujarid A
[Ad] Endereço:Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India.
[Ti] Título:A rapid and sensitive determination of hypoxic radiosensitizer agent nimorazole in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.
[So] Source:Biomed Chromatogr;29(10):1575-80, 2015 Oct.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A highly sensitive, accurate and robust LC-MS/MS method was developed and validated for determination of nimorazole (NMZ) in rat plasma using metronidazole (MNZ) as internal standard (IS). The analyte and IS were extracted from plasma by precipitating protein with acetonitrile and were chromatographed using an Agilent Poroshell 120, EC-C18 column. The mobile phase was composed of a mixture of acetonitrile and 0.1 % formic acid (85:15 v/v). The total run time was 1.5 min and injection volume was 5 µL. Multiple reaction monitoring mode using the transitions of m/z 227.1 → m/z 114.0 for MNZ and m/z 172.10 → m/z 128.1 for IS were monitored on a triple quadrupole mass spectrometer, operating in positive ion mode. The calibration curve was linear in the range of 0.25-200 ng/mL (r(2) > 0.9996) and the lower limit of quantification was 0.25 ng/mL in the rat plasma samples. Recoveries of NMZ ranged between 88.05 and 95.25%. The precision (intra-day and inter-day) and accuracy of the quality control samples were 1.25-8.20% and -2.50-3.10, respectively. The analyte and IS were found to be stable during all sample storage and analysis procedures. The LC-MS/MS method described here was validated and successfully applied to pharmacokinetic study in rats.
[Mh] Termos MeSH primário: Cromatografia Líquida/métodos
Nimorazol/sangue
Nimorazol/farmacocinética
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Animais
Área Sob a Curva
Calibragem
Fracionamento Químico/métodos
Estabilidade de Medicamentos
Masculino
Metronidazol/sangue
Radiossensibilizantes/farmacocinética
Ratos Wistar
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents); 140QMO216E (Metronidazole); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150909
[Lr] Data última revisão:
150909
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150408
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.3461


  6 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25629651
[Au] Autor:Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
[Ad] Endereço:Department of Oncology, Herlev Hospital , Herlev , Denmark.
[Ti] Título:Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
[So] Source:Acta Oncol;54(7):1001-7, 2015 Jul.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE/OBJECTIVE: A phase II clinical trial evaluating the feasibility and outcome of treating locally advanced head and neck squamous cell carcinoma (HNSCC) with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. MATERIAL AND METHODS: A total of 227 patients with stage III or IV HNSCC of the larynx, oropharynx, hypopharynx, or oral cavity where included between January 2007 and December 2010. The prescribed radiotherapy (RT) dose was 66-68 Gy in 2 Gy fractions, 6 F/W. The hypoxic radiosensitiser nimorazole was given orally at a dose of 1200 mg/m(2) before each fraction. Concomitant cisplatin (40 mg/m(2)) i.v. was given once a week for a maximum of six cycles. Outcome data were evaluated in terms of loco-regional tumour control (LRC), event-free survival (EFS) and overall survival (OS). Morbidity data were evaluated based on the DAHANCA routine registration. Human papillomavirus (HPV)-status was estimated by immunohistochemical staining of p16. RESULTS: Included were 178 (78%) men and 49 (22%) women with a median age of 57 years. All except five patients received RT as prescribed. At least five series of cisplatin was given to 164 (72%) of the patients, and 149 patients (66%) received the full dose of nimorazole. The five-year actuarial LRC, EFS and OS rates were 80%, 67% and 72%, respectively. The LRC rates according to site were: oropharynx: 88%, larynx: 77%, hypopharynx 72% and oral cavity 49%, respectively. HPV/p16 staining was obtained in 141 of the 150 oropharyngeal cancers. Of these, 112 (79%) were p16 pos and 29 (21%) were p16 neg. LRC for the p16 neg oropharyngeal cancers was poorer than for the p16 pos (74% vs. 91%; p = 0.02). Tube feeding during treatment was necessary for 146 (64%) patients. At 12 months this number was reduced to 6%. CONCLUSION: The treatment was tolerable in this cohort of locally advanced HNSCC patients. Acute and late toxicity was comparable to similar studies of chemoradiotherapy, and the outcome superior to the data reported in the literature. This strongly indicates that RT of advanced head and neck cancer must include as well hypoxic modification, accelerated fractionation as chemoradiotherapy to yield optimal outcome.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma de Células Escamosas/tratamento farmacológico
Carcinoma de Células Escamosas/radioterapia
Quimiorradioterapia/métodos
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Neoplasias de Cabeça e Pescoço/radioterapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Carcinoma de Células Escamosas/mortalidade
Quimiorradioterapia/efeitos adversos
Cisplatino/administração & dosagem
Cisplatino/efeitos adversos
Intervalo Livre de Doença
Feminino
Neoplasias de Cabeça e Pescoço/mortalidade
Seres Humanos
Masculino
Meia-Idade
Nimorazol/administração & dosagem
Nimorazol/efeitos adversos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
469ULX0H4G (Nimorazole); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:150605
[Lr] Data última revisão:
150605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150129
[St] Status:MEDLINE
[do] DOI:10.3109/0284186X.2014.992547


  7 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25616539
[Au] Autor:Tran LB; Bol A; Labar D; Cao-Pham TT; Jordan B; Grégoire V; Gallez B
[Ad] Endereço:Louvain Drug Research Institute, Biomedical Magnetic Resonance Research Group, Université catholique de Louvain, Brussels, Belgium.
[Ti] Título:Predictive value of (18)F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: a preclinical study.
[So] Source:Radiother Oncol;114(2):189-94, 2015 Feb.
[Is] ISSN:1879-0887
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the predictive value of hypoxia imaging by (18)F-FAZA PET in identifying tumors that may benefit from radiotherapy combined with nimorazole, a hypoxic radiosensitizer. MATERIAL AND METHODS: Rats of two tumor models (Rhabdomyosarcoma and 9L-glioma) were divided into two treated groups: radiotherapy (RT) alone or RT plus nimorazole. (18)F-FAZA PET images were obtained to evaluate tumor hypoxia before the treatment. Treatment outcome was assessed through the tumor growth time assay, defined as the time required for tumor to grow to 1.5 times its size before irradiation. RESULTS: For rhabdomyosarcomas, the benefit of adding nimorazole to RT was not significant when considering all tumors. When stratifying into more and less hypoxic tumors according to the median (18)F-FAZA T/B ratio, we found that the combined treatment significantly improved the response of the "more hypoxic" subgroup, while there was no significant difference in the tumor growth time between the two treatment modalities for the "less hypoxic" subgroup. For 9L-gliomas, a clear benefit was demonstrated for the group receiving RT+nimorazole. However, the individual responses within the RT+nimorazole group were highly variable and independent of the (18)F-FAZA uptake. CONCLUSIONS: (18)F-FAZA PET may be useful to guide hypoxia-directed RT using nimorazole as radiosensitizer. It identified a subgroup of more hypoxic tumors (displaying T/B ratio>2.72) that would benefit from this combined treatment. Nevertheless, the predictive power was limited to rhabdomyosarcomas and ineffective for 9L-gliomas.
[Mh] Termos MeSH primário: Glioma/diagnóstico por imagem
Glioma/terapia
Nimorazol/farmacologia
Nitroimidazóis
Rabdomiossarcoma/diagnóstico por imagem
Rabdomiossarcoma/terapia
[Mh] Termos MeSH secundário: Animais
Hipóxia Celular/fisiologia
Quimiorradioterapia
Modelos Animais de Doenças
Radioisótopos de Flúor
Glioma/tratamento farmacológico
Glioma/radioterapia
Masculino
Tomografia por Emissão de Pósitrons/métodos
Compostos Radiofarmacêuticos
Distribuição Aleatória
Ratos
Ratos Endogâmicos F344
Rabdomiossarcoma/tratamento farmacológico
Rabdomiossarcoma/radioterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fluorine Radioisotopes); 0 (Nitroimidazoles); 0 (Radiopharmaceuticals); 1QR3UU6P48 (fluoroazomycin arabinoside); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150125
[St] Status:MEDLINE


  8 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25530485
[Au] Autor:Hassan Metwally MA; Jansen JA; Overgaard J
[Ad] Endereço:Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: hassan@oncology.dk.
[Ti] Título:Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
[So] Source:Clin Oncol (R Coll Radiol);27(3):168-75, 2015 Mar.
[Is] ISSN:1433-2981
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: To study the pharmacokinetic characteristics of the hypoxic radiosensitiser nimorazole in patients with head and neck squamous cell carcinoma. MATERIALS AND METHODS: The pharmacokinetics of the hypoxic radiosensitiser nimorazole were studied in 63 patients treated in the DAHANCA-5 trial. After the first day of treatment, serial venous blood samples were taken and plasma concentrations of nimorazole measured by high pressure liquid chromatography (HPLC). Plasma concentration profiles were subjected to non-compartmental pharmacokinetic analysis using validated PC-based software. The different pharmacokinetic parameters were calculated and correlated with the different patient- and treatment-related variables. RESULTS: HPLC measurements showed a linear relationship between peak plasma concentration and administered dose. The mean peak concentration adjusted for dose (in g/m(2)) was 32.2 ± 0.9 µg/ml. The time of peak concentration ranged between 30 and 180 min (median 60 min). Plasma elimination occurred with a mean half-life of 3.35 ± 0.09 h and was not significantly altered as a function of dose. There was a well-established linear-linear relationship between area under the concentration-time curve (AUC; mean 191 ± 6 µg·h/ml) and administered dose, especially when expressed as g/m(2). The mean apparent volume of distribution was 0.77 ± 0.02 l/kg. A statistically significant longer elimination half-life in men relative to women (mean difference 0.40 h; 95% confidence interval 0.77-0.03; P 0.03) was detected. Nimorazole was well tolerated; with 67% of patients reporting no toxicity; nausea/vomiting was the most reported toxicity in the remaining patients. CONCLUSION: The study supports the current nimorazole dose scheduling in patients.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/tratamento farmacológico
Carcinoma de Células Escamosas/metabolismo
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Neoplasias de Cabeça e Pescoço/metabolismo
Nimorazol/farmacocinética
Radiossensibilizantes/farmacocinética
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células Escamosas/sangue
Feminino
Neoplasias de Cabeça e Pescoço/sangue
Seres Humanos
Masculino
Meia-Idade
Nimorazol/administração & dosagem
Nimorazol/efeitos adversos
Nimorazol/sangue
Radiossensibilizantes/administração & dosagem
Radiossensibilizantes/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:150209
[Lr] Data última revisão:
150209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141223
[St] Status:MEDLINE


  9 / 74 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24685344
[Au] Autor:Thomson D; Yang H; Baines H; Miles E; Bolton S; West C; Slevin N
[Ad] Endereço:Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK; Institute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK.
[Ti] Título:NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.
[So] Source:Clin Oncol (R Coll Radiol);26(6):344-7, 2014 Jun.
[Is] ISSN:1433-2981
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/tratamento farmacológico
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Nimorazol/administração & dosagem
Radiossensibilizantes/administração & dosagem
Radioterapia de Intensidade Modulada/métodos
[Mh] Termos MeSH secundário: Antitricômonas/administração & dosagem
Carcinoma de Células Escamosas/radioterapia
Hipóxia Celular
Terapia Combinada
Neoplasias de Cabeça e Pescoço/radioterapia
Seres Humanos
Projetos de Pesquisa
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; EDITORIAL; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antitrichomonal Agents); 0 (Radiation-Sensitizing Agents); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140402
[St] Status:MEDLINE


  10 / 74 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24328536
[Au] Autor:Metwally MA; Frederiksen KD; Overgaard J
[Ad] Endereço:Department of Experimental Clinical Oncology, Aarhus University Hospital , Aarhus , Denmark.
[Ti] Título:Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
[So] Source:Acta Oncol;53(5):654-61, 2014 May.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the compliance and toxicity of the hypoxic radiosensitizer nimorazole in head and neck cancer patients. METHODS: A retrospective study of patients with head and neck squamous cell carcinoma (HNSCC), treated in Denmark between 1990 and 2013. All patients treated with radical radiotherapy (± chemotherapy) [66-70 Gy; 33-35 fractions; 2 Gy/fraction; 5-6 fractions/week] concomitant with the hypoxic radiosensitizer nimorazole. Nimorazole was administered as oral tablets in doses of approximately 1.2 g/m(2) body surface area in connection with the first of each daily radiation treatment. A second daily dose of 1 g was given in connection with the second radiotherapy fraction in the accelerated fractionation regimen. The compliance was estimated as the percentage of the initially prescribed dose, which was received by each patient. The main side effects were recorded. RESULTS: A total of 1049 patients were investigated. The tolerance to nimorazole was fair: 58% of patients received the full prescribed total dose. Nausea and vomiting were the major complaints: among the 260 patients with dose reductions due to known side effects, (87%) were due to nausea/vomiting. All side effects ceased when treatment was interrupted, and neither severe nor long lasting side effects were observed. Female patients were significantly more likely to have dose reduction (OR 2.02; 95% CI 1.50-2.70), and nausea/vomiting. Patients aged more than 70 years were significantly more likely to have dose reduction. Patients who received less than 1100 mg/m(2) were significantly less likely to have dose reduction (OR 0.58; CI 0.44-0.78), and nausea/vomiting, compared to those who received 1100-1300 mg/m(2). The tolerance was also less in the group of patients received accelerated chemoradiotherapy (OR 1.70; CI 1.20-2.50) with more association with nausea/vomiting (OR 2.09; CI 1.40-3.10). CONCLUSION: The compliance to nimorazole is fair, with tolerable acute, but neither persistent nor late, toxicity. It can be administered with chemotherapy and different radiotherapy fractionation schedules.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/tratamento farmacológico
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Adesão à Medicação
Nimorazol/efeitos adversos
Radiossensibilizantes/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Carcinoma de Células Escamosas/radioterapia
Relação Dose-Resposta a Droga
Feminino
Neoplasias de Cabeça e Pescoço/radioterapia
Seres Humanos
Masculino
Meia-Idade
Nimorazol/administração & dosagem
Radiossensibilizantes/administração & dosagem
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents); 469ULX0H4G (Nimorazole)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:140414
[Lr] Data última revisão:
140414
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131217
[St] Status:MEDLINE
[do] DOI:10.3109/0284186X.2013.864050



página 1 de 8 ir para página                    
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde